PL3349599T3 - Wziewne preparaty nikotyny oraz sposoby ich wytwarzania i zastosowania - Google Patents

Wziewne preparaty nikotyny oraz sposoby ich wytwarzania i zastosowania

Info

Publication number
PL3349599T3
PL3349599T3 PL16847315.5T PL16847315T PL3349599T3 PL 3349599 T3 PL3349599 T3 PL 3349599T3 PL 16847315 T PL16847315 T PL 16847315T PL 3349599 T3 PL3349599 T3 PL 3349599T3
Authority
PL
Poland
Prior art keywords
production
methods
inhalable nicotine
nicotine preparations
preparations
Prior art date
Application number
PL16847315.5T
Other languages
English (en)
Inventor
Alex Stenzler
Noe Zamel
Arthur Slutsky
Steven Ellis
Original Assignee
Philip Morris Products S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philip Morris Products S.A. filed Critical Philip Morris Products S.A.
Publication of PL3349599T3 publication Critical patent/PL3349599T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
    • A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
    • A24B15/36—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring
    • A24B15/40—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances containing a heterocyclic ring having only oxygen or sulfur as hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PL16847315.5T 2015-09-16 2016-09-15 Wziewne preparaty nikotyny oraz sposoby ich wytwarzania i zastosowania PL3349599T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/856,102 US9585835B1 (en) 2015-09-16 2015-09-16 Inhalable nicotine formulations and methods of making and using the same
PCT/US2016/051963 WO2017048974A1 (en) 2015-09-16 2016-09-15 Inhalable nicotine formulations, and methods of making and using thereof

Publications (1)

Publication Number Publication Date
PL3349599T3 true PL3349599T3 (pl) 2025-03-24

Family

ID=58162192

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16847315.5T PL3349599T3 (pl) 2015-09-16 2016-09-15 Wziewne preparaty nikotyny oraz sposoby ich wytwarzania i zastosowania

Country Status (19)

Country Link
US (1) US9585835B1 (pl)
EP (1) EP3349599B1 (pl)
JP (3) JP7575183B2 (pl)
KR (1) KR102760317B1 (pl)
CN (1) CN106539794B (pl)
AU (1) AU2016323317A1 (pl)
BR (1) BR112018005145B1 (pl)
CA (1) CA2999082A1 (pl)
ES (1) ES2997334T3 (pl)
HK (1) HK1258016A1 (pl)
IL (1) IL258143A (pl)
MX (1) MX394985B (pl)
MY (1) MY184362A (pl)
PH (1) PH12018500544A1 (pl)
PL (1) PL3349599T3 (pl)
RU (1) RU2719228C2 (pl)
UA (1) UA126849C2 (pl)
WO (1) WO2017048974A1 (pl)
ZA (1) ZA201801569B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968125B2 (en) * 2015-01-09 2018-05-15 Philip Morris Products S.A. Nicotine—diketopiperazine microparticle formulations and methods of making the same
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US11224594B2 (en) 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
RU2767064C2 (ru) * 2016-06-30 2022-03-16 Филип Моррис Продактс С.А. Никотиносодержащие частицы и композиции
CN110300588A (zh) * 2017-03-07 2019-10-01 菲利普莫里斯生产公司 可吸入尼古丁调配物及其制造和使用方法
IL269275B2 (en) 2017-06-28 2023-04-01 Philip Morris Products Sa Container with particles for use with an inhaler
GB201817868D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
GB201817862D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolisable formulation
KR20220098778A (ko) * 2019-11-14 2022-07-12 필립모리스 프로덕츠 에스.에이. 개선된 담배 향이 나는 건조 분말 제형
EP4164595B1 (en) * 2020-06-15 2025-08-20 Philip Morris Products S.A. Anatabine powder compositions
US20220313614A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Encapsulated nicotine granules and methods of preparation thereof
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
CN120417888A (zh) * 2022-10-27 2025-08-01 韩国烟草人参公社 用于吸入的尼古丁干粉的制备方法
WO2024090890A1 (ko) * 2022-10-27 2024-05-02 주식회사 케이티앤지 흡입용 저용량 니코틴 건조 분말 조성물
CN117158443B (zh) * 2023-09-05 2024-03-22 贵州大学 烟碱在制备贝莱斯芽胞杆菌生防作用增强剂中的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441060A (en) 1993-02-08 1995-08-15 Duke University Dry powder delivery system
CA2146954C (en) 1995-04-12 2008-06-17 Arthur Slutsky Breath activated nicotine inhalers
AUPN862596A0 (en) * 1996-03-12 1996-04-04 F.H. Faulding & Co. Limited Pharmaceutical compositions
DE69830158T2 (de) * 1997-09-22 2006-02-23 Ohshiro Co., Ltd., Kawasaki Regulierer für tabakraucharoma
CA2265198C (en) 1998-03-11 2009-01-27 Zamel, Noe Method of producing a nicotine medicament and a medicament made by the method
US20120042886A1 (en) 1998-03-11 2012-02-23 Hanna Piskorz Method of producing a nicotine medicament and a medicament made by the method
CA2231968A1 (en) 1998-03-11 1999-09-11 Smoke-Stop, A Partnership Consisting Of Art Slutsky Method of producing a nicotine medicament
US6234169B1 (en) 1998-08-14 2001-05-22 Arthur Slutsky Inhaler
ES2395096T3 (es) 1999-06-29 2013-02-08 Mannkind Corporation Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US8256433B2 (en) 1999-07-16 2012-09-04 Aradigm Corporation Systems and methods for effecting cessation of tobacco use
US6799576B2 (en) 1999-07-16 2004-10-05 Aradigm Corporation System for effecting smoking cessation
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
JP2003519175A (ja) 1999-12-30 2003-06-17 カイロン コーポレイション インターロイキン−２の肺送達のための方法
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
KR20030038690A (ko) 2000-08-07 2003-05-16 인헤일 테라퓨틱 시스템즈 인크. 응집이 최소화된, 흡입성 분무 건조 4-나선 다발 단백질분말
FR2815987B1 (fr) 2000-10-27 2003-02-28 Michel Petiot Embase enfichable pour poteau ou piquet
JP2002161030A (ja) 2000-11-27 2002-06-04 Unisia Jecs Corp 異なる粒径をもった混合粉体の吸入方法
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
ATE359075T1 (de) 2002-12-20 2007-05-15 Niconovum Ab Chemisch und physikalisch stabiles teilchenförmiges material enthaltend nikotin und microcrystalline cellulose
EP1617820B1 (en) 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
CA2523475C (en) 2003-05-28 2013-02-05 Nektar Therapeutics Pharmaceutical formulation comprising a water-insoluble active agent
MXPA06002609A (es) 2003-09-08 2006-06-05 Pfizer Health Ab Formulaciones de nicotina y uso de las mismas.
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
SE528121C2 (sv) * 2004-03-29 2006-09-05 Mederio Ag Preparering av torrpulver för på förhand uppmätt DPI
GB0410398D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
ATE553074T1 (de) * 2004-05-24 2012-04-15 British American Tobacco Co Molekular geprägte, nitrosaminselektive polymere und verfahren zu deren anwendung
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006124448A2 (en) * 2005-05-11 2006-11-23 Vector Tobacco Inc. Reduced risk tobacco products and methods of making same
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
EP1973523A2 (en) 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US8257685B2 (en) 2006-04-04 2012-09-04 Stc.Unm Swellable particles for drug delivery
FI20060428L (fi) * 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
EP2086527A4 (en) 2006-12-01 2010-03-03 Aradigm Corp SYSTEMS FOR IMPACT OF TOBACCO ABSTINENCE
GB0709811D0 (en) * 2007-05-22 2007-07-04 Vectura Group Plc Pharmaceutical compositions
GB0712308D0 (en) 2007-06-25 2007-08-01 Kind Group Ltd An inhalable composition
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
GB0905840D0 (en) * 2009-04-06 2009-05-20 Sagentia Ltd Apparatus and methods
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
EP2729148A4 (en) * 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
PT2739268T (pt) * 2011-08-01 2019-01-28 Univ Monash Método e formulação para inalação
GB201113662D0 (en) 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US20130177646A1 (en) 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
GB201215273D0 (en) * 2012-08-28 2012-10-10 Kind Consumer Ltd Nicotine composition
US20140088045A1 (en) * 2012-09-21 2014-03-27 Basil Rigas Product comprising a nicotine-containing material and an anti-cancer agent
US20140166027A1 (en) 2012-12-14 2014-06-19 Richard C. Fuisz Enhanced Delivery of Nicotine, THC, Tobacco, Cannabidiol or Base Alkaloid from an Electronic Cigarette or Other Vapor Producing Device Through Use of an Absorption Conditioning Unit
US20140261474A1 (en) * 2013-03-15 2014-09-18 Aradigm Corporation Methods for inhalation of smoke-free nicotine
EP3129024A4 (en) * 2014-04-08 2017-11-22 Sansa Corporation (Barbados) Inc. Nicotine formulations and methods of making the same
KR102428028B1 (ko) 2014-04-28 2022-08-03 필립모리스 프로덕츠 에스.에이. 향미를 가진 니코틴 분말 흡입기
MX381937B (es) 2014-04-28 2025-03-13 Philip Morris Products Sa Inhalador de polvo de nicotina.
FR3035826B1 (fr) * 2015-05-07 2018-11-16 Saint-Gobain Glass France Vitrage de vehicule comprenant une platine pour la fixation de plusieurs accessoires, platine et procede de fixation.
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same

Also Published As

Publication number Publication date
AU2016323317A1 (en) 2018-04-12
JP2024086897A (ja) 2024-06-28
EP3349599A4 (en) 2019-04-17
UA126849C2 (uk) 2023-02-15
ES2997334T3 (en) 2025-02-17
CN106539794B (zh) 2020-05-15
US9585835B1 (en) 2017-03-07
KR20180077150A (ko) 2018-07-06
US20170071856A1 (en) 2017-03-16
HK1258016A1 (zh) 2019-11-01
EP3349599C0 (en) 2024-11-20
MX394985B (es) 2025-03-24
PH12018500544A1 (en) 2018-09-24
EP3349599A1 (en) 2018-07-25
WO2017048974A8 (en) 2018-04-12
JP7575183B2 (ja) 2024-10-29
RU2018113460A (ru) 2019-10-18
EP3349599B1 (en) 2024-11-20
CN106539794A (zh) 2017-03-29
MX2018003272A (es) 2018-08-16
KR102760317B1 (ko) 2025-02-03
CA2999082A1 (en) 2017-03-23
BR112018005145A2 (pt) 2018-12-11
RU2018113460A3 (pl) 2019-10-18
IL258143A (en) 2018-05-31
WO2017048974A1 (en) 2017-03-23
JP2018528966A (ja) 2018-10-04
RU2719228C2 (ru) 2020-04-17
BR112018005145B1 (pt) 2022-05-03
JP2022097639A (ja) 2022-06-30
ZA201801569B (en) 2019-01-30
MY184362A (en) 2021-04-01

Similar Documents

Publication Publication Date Title
PL3349599T3 (pl) Wziewne preparaty nikotyny oraz sposoby ich wytwarzania i zastosowania
IL289527B (en) Nicotine liquid formulations for aerosol devices and methods thereof
IL271736A (en) Nicotine salts, and methods for their preparation and use
IL255269A (en) Compositions of obeticholic acid and methods of use
IL262301A (en) Liposomal preparation and methods of treatment
IL256652A (en) Therapeutic compositions, combinations, and methods of use
IL282048A (en) Oxysterols and methods of use thereof
IL246383A0 (en) Polyoxometalate and heteropolyoxometalate compositions and methods for their use
IL259747A (en) Antibodies targeting fc receptor-like 5 and methods of use
PL3250610T3 (pl) Przeciwciała anty-FcRn i sposoby ich stosowania
IL254039A0 (en) Anti-pvrig antibodies and methods of use
PL3215532T3 (pl) Przeciwciała anty-TIM3 i sposoby ich zastosowania
PL3828194T3 (pl) Oksysterole i sposoby ich stosowania
EP3423058A4 (en) NICOTINE FORMULATION AND AEROSOLS
IL242394B (en) Cenicriviroc compositions and methods of making and using the same
IL252602B (en) Oral care compositions and methods of use
HUE046756T2 (hu) Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei
LT4000608T (lt) Farmacinė kompozicija, gydymo būdai ir jų panaudojimas
PL3371206T3 (pl) Sposoby wytwarzania postaci fukozylowanej i niefukozylowanej białka
DK3024497T3 (da) Fremgangsmåder og præparater til behandling af hjernesygdomme
IL256322B (en) Improved formulations of deferasirox and methods of making the same
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
LT3341027T (lt) Transfekcijos kompleksai ir jų panaudojimo būdai
IL265881A (en) Inhaler and methods of use thereof
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości